iStock

Ultrasound used to burst chemo-capsules inside tumours

Embargoed until: Publicly released:

The safety green light has been given to a new cancer treatment that delivers cancer drugs straight to liver tumours before using ultrasound to remotely rupture the capsule – releasing the chemo directly into the tumour. The UK phase 1 clinical trial found the technique was safe and can supply three times more drugs to a tumour than the unruptured capsule – though a larger trial is needed to determine its effectiveness. An accompanying comment piece says the trial shows promise and that the treatment could be used on all sorts of solid tumours because the drug is used to reduce tumours in a number of cancers.

Journal/conference: The Lancet Oncology

DOI: 10.1016/ S1470-2045(18)30419-4

Organisation/s: University of Oxford, UK

Funder: Funded by the National Institute for Health Research Oxford Biomedical Research Centre.

Media Release

From: The Lancet

Heat-activated lipid capsules directed by ultrasound increase chemotherapy delivery in liver tumours

A phase 1 clinical trial testing heat-sensitive lipid capsules filled with chemotherapy, which are ruptured remotely using ultrasound, has found that the technique increased the amount of chemotherapy delivered directly to liver tumours, according to research published in The Lancet Oncology journal. 

The study of 10 people is the first of its kind, and suggests that the technique is safe to use, but more research will be needed to assess its effectiveness in treating liver tumours.

“Reaching therapeutic levels of cancer drugs within a tumour, while avoiding side effects for the rest of the body is a challenge for all cancer drugs, including small molecules, antibodies and viruses,” says Professor Constantin Coussios, University of Oxford, UK. “Our study is the first to trial this new technique in humans, and finds that it is possible to safely trigger and target the delivery of chemotherapy deep within the body using focussed ultrasound. Once inside the tumour, the lipid capsules release the drug, supplying a higher dose of chemotherapy directly to the tumour, which may help to treat tumours more effectively.” [1]

Other clinical trials have combined the chemotherapy-filled lipid capsules, with radiofrequency ablation, which uses the heat made by radio waves to kill cancer cells, but this study is the first to use ultrasound to remotely trigger drug release from the capsules. Previous preclinical research has suggested that this combination could increase the concentration of chemotherapy within a tumour, and how far it penetrates into the tumour. 

The open-label phase 1 trial was conducted in one hospital in the UK, and included 10 patients with incurable tumours in their livers – including cancers of the liver, as well as tumours that had spread to the liver from other areas of the body. The patients had already received standard chemotherapy to help control their tumours, and the trial analysed the safety and feasibility of the new technique. 

The technique is completed under general anaesthetic. A dose of 50mg/m2 of doxorubicin chemotherapy within heat-sensitive lipid capsules is injected into each patient’s bloodstream. A beam of ultrasound was then focussed on the liver tumour, slightly increasing the temperature in that area. Above 39.5⁰C, the capsules release the drug into the bloodstream inside the tumour. This then creates a high drug concentration gradient, driving more chemotherapy into the tumour. 

The researchers measured how much ultrasound exposure was needed to heat the tumour to 39.5⁰C or higher by temporarily implanting a heat-recording device placed into six patients’ tumours. They also took tumour biopsies from all 10 patients to assess the amount of chemotherapy delivered inside the tumour. 

In seven out of 10 patients, chemotherapy concentrations within the liver tumour were two or more times higher after the ultrasound, compared with before ultrasound exposure, when there was only passive build-up of chemotherapy from the liposomes in the tumour. The concentration of chemotherapy within the tumour was less than doubled in the other three patients. On average, the new technique increased the amount of chemotherapy inside the tumour by 3.7 times (from 2.34 µg/g chemotherapy within the tumour before ultrasound exposure, to 8.56 µg/g chemotherapy within the tumour after ultrasound exposure). 

Side effects were monitored for 30 days after the procedure. Apart from the expected side effects caused by general anaesthetic and chemotherapy, the procedure posed no additional risks. Five patients had grade 4 neutropenia but their symptoms were resolved without treatment. One patient experienced mild confusion after the procedure, and was kept in hospital until this resolved. 

The authors note some limitations, including that the biopsies only looked at one region of the tumour. As tumours can be highly varied, the biopsies can only estimate how much chemotherapy has entered the full tumour. The authors also note that their trial did not include a control group treated with liposomes only, and that in certain patients the size of the tumour that can be treated is limited, because the patient’s ribs block the ultrasound beam. More research will be needed to confirm whether the technique improves clinical outcomes for patients. 

Writing in a linked Comment, Professor Dieter Haemmerich, Medical University of South Carolina, USA, notes that the study could be a beneficial non-invasive treatment option for patients with solid tumours. He also notes: “There are areas in which the approach by Lyon and colleagues might be further improved. In most patients, tumours were only partly exposed to hyperthermia (and, presumably, to the drug), suggesting that an improved hyperthermia device or heating strategy is necessary, especially for larger tumours… Nevertheless, Lyon and colleagues’ study represents a first important step towards clinical translation of this elegant targeted drug delivery approach, by demonstrating the ability to locally enhance drug uptake, while showing therapeutic response with a drug that traditionally had low efficacy in liver cancer. Although the investigators showed the safety, feasibility, and therapeutic potential of lyso-thermosensitive liposomal doxorubicin (LTLD) in patients with liver cancer, the described focused ultrasound plus LTLD approach might be more widely applicable to other solid tumours because doxorubicin is a wide-spectrum antitumour drug.”

Attachments:

  • The Lancet
    Web page
    The URL will go live after the embargo ends

News for:

International

Media contact details for this story are only visible to registered journalists.